Freespira Receives FDA Clearance for Adolescents Ages 13–17; Clinically Validated, At-Home Treatment Reduces Panic Disorder Symptom Severity by 54% and PTSD Symptom Severity by 44%
Freespira, Inc., developer of the first FDA-cleared at-home treatment for anxiety disorders, including panic disorder (PD), and post-traumatic stress disorder (PTSD), today announced FDA 510(k) clearance (K233337), extending its indications to adolescents aged 13–17. This milestone positions Freespira as the only prescription, medication-free treatment explicitly targeting physiological root causes of panic attacks and PTSD symptoms through real-time, software-driven respiratory guidance and 1:1 video coaching to correct the respiratory dysfunction commonly underlying these disorders.
Freespira and WellCare of Kentucky Bring Life-Changing Treatment to Panic Disorder and PTSD Sufferers
Freespira, Inc., developer of the only FDA-cleared at-home treatment for panic disorder, anxiety attacks, and post-traumatic stress disorder (PTSD) symptoms, today announced a new pilot program with WellCare of Kentucky, a leading Medicaid health plan. Eligible WellCare of Kentucky members will now have access to Freespira’s proven treatment, which helps patients stabilize their breathing patterns to reduce panic attacks and PTSD symptoms.
